[Minimal useful dose of combined cytostatics in the treatment of inoperable pulmonary cancer].
D000230:Adenocarcinoma / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002277:Carcinoma / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004357:Drug Synergism; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D008937:Mitomycins / Q000008:administration & dosage; D009362:Neoplasm Metastasis / Q000188:drug therapy; D011879:Radiotherapy Dosage; D014228:Triaziquone / Q000008:administration & dosage
D000970:Antineoplastic Agents; D008937:Mitomycins; D003609:Dactinomycin; D003520:Cyclophosphamide; D015122:Mercaptopurine; D014228:Triaziquone; D008727:Methotrexate
Dose minimale utile de cytostatiques associés dans le traitement du cancer pulmonaire inopérable.